Pact adds cost effectiveness to drug study

Up to now, researchers have been primarily interested in studying efficacy and safety in clinical trials. After today, you may have to start adding efficiency to the list of R&D focuses. Novartis has cut a deal with the UK's drug watchdog--NICE--to determine the cost effectiveness of an experimental therapy, according to the Financial Times. The watchdog will pocket a consultancy fee to outline what researchers will need to determine in studying costs associated with the drug, code named Novartis 001, in a Phase III trial. The move marks yet another advantage for UK officials in negotiating with drug developers. Manufacturers have already begun to offer better terms to the British government's drug agencies, an advantage of a single-payer system that can stiff-arm medications that it finds are not cost efficient.

- here's the report from the Financial Times
- and here's the report from Thomson Financial

ALSO: None of the new studies will be undertaken in Vienna, though. Novartis says it will close its research facility there as part of its global restructuring. Report

Related Articles:
Where's the ROI on drug R&D budgets? Report
UK accepts J&J's money-back guarantee. Report
Lagging sales spur Novartis layoffs. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.